Article Text

Download PDFPDF
Improving timeliness of hepatitis B vaccine administration in an urban safety net level III NICU
  1. Madoka Hayashi1,2,3,
  2. Theresa R Grover2,3,
  3. Steve Small1,
  4. Tessa Staples1,
  5. Genie Roosevelt4,5
  1. 1Department of Pediatrics, Denver Health and Hospital Authority, Denver, CO, USA
  2. 2Department of Pediatrics, Section of Neonatology, University of Colorado School of Medicine, Aurora, CO, USA
  3. 3Department of Pediatrics, Section of Neonatology, Children’s Hospital Colorado, Aurora, CO, USA
  4. 4Department of Emergency Medicine, Denver Health and Hospital Authority, Denver, CO, USA
  5. 5Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, CO, USA
  1. Correspondence to Dr Madoka Hayashi, Department of Pediatrics, Denver Health and Hospital Authority, Denver, CO 80204, USA; madoka.hayashi{at}dhha.org

Abstract

Objective To avoid preventable consequences of perinatal hepatitis B infection, all infants should be given hepatitis B vaccine (HBV) within 24 hours of birth if birth weight is ≥2 kg and at 30 days of life or at discharge if <2 kg, to provide highest seroprotection rates while ensuring universal vaccination prior to discharge. We aimed to achieve timely HBV administration in >80% of eligible infants in both birthweight groups and decrease infants discharged home without receiving HBV to <1% over an 18-month period and sustain results for an additional 15 months.

Methods Data were collected from June 2016 to May 2020 in a level III neonatal intensive care unit. A multidisciplinary team identified barriers and interventions through Plan-Do-Study-Act cycles from September 2017 to February 2019: using pharmacists as champions, overcoming legal barriers, staff education and best practice alerts (BPAs) embedded in electronic health records. Statistical process control (SPC) p charts were used to evaluate the primary outcome measure, monthly percentage of infants receiving timely HBV administration stratified by birthweight categories (≥2 and <2 kg). For infants receiving HBV outside the time frame, absolute difference of timeliness was calculated.

Results Mean timely HBV administration improved from 45% to 95% (≥2 kg) and from 45% to 85% (<2 kg) with special cause variation in SPC charts. Infants discharged without receiving HBV decreased from 4.6% to 0.22%. Of those given HBV outside the recommended time frame, median absolute time between recommended and actual administration time decreased significantly: from 3.5 days (IQR 1.6, 8.6) to 0.3 day (IQR 0.1, 0.8) (p<0.001) in ≥2 kg group and from 6 days (IQR 1, 15) to 1 day (IQR 1, 6.5) (p=0.009) in <2 kg group.

Conclusions Using a multidisciplinary approach, we significantly improved and sustained timely HBV administration and nearly eliminated infants discharged home without receiving HBV. Pharmacists as champions and BPAs were critical to our success.

  • paediatrics
  • control charts
  • run charts
  • quality improvement
  • PDSA
  • hospital medicine

Data availability statement

Data are available upon reasonable request. Please contact the corresponding author to discuss the feasibility of obtaining access to a deidentified data set.

Statistics from Altmetric.com

Data availability statement

Data are available upon reasonable request. Please contact the corresponding author to discuss the feasibility of obtaining access to a deidentified data set.

View Full Text

Footnotes

  • Contributors MH conceptualised and designed the study and data collection method, collected data, carried out the initial analyses and interpretation, drafted the initial manuscript and reviewed and revised the manuscript. TRG interpreted the data and reviewed and revised the manuscript for important intellectual content. SS conceptualised and designed the study, collected data and reviewed and revised the manuscript. TS conceptualised and designed the study and reviewed and revised the manuscript. GR collected data, analysed and interpreted the data and reviewed and revised the manuscript for important intellectual content. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles